Understanding How to Best Conduct Long-Term Safety Monitoring
Time: 12:00 pm
day: Day Two
Details:
• Assessing the current FDA guidelines
• Reviewing how effective long-term follow up protocol is at truly understanding the long-term safety of AAV gene therapies
• Strategize additional monitoring to better inform the long-term safety profile
